Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet transfusion: a dose-response study

F Norol1, P Bierling, F Roudot-Thoraval

  • 1ETS Sud-Est Francilien, Hôpital Henri Mondor, Creteil; Unité Evaluation Etude, Hôpital Henri Mondor, Creteil, France.

Blood
|August 8, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delayed hemolytic transfusion reaction in the French hemovigilance system.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2019
Same author

[Is the research of posttransfusional alloantibodies still relevant?]

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2017
Same author

Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.

Alimentary pharmacology & therapeutics·2017
Same author

[Is transplantation an alternative to the transfusional impasse in sickle cell disease?]

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2017
Same author

Polyvalent immunoglobulins, platelet lysate and lenalidomide: cocktail for polyfunctional NK cells expansion for multiple myeloma.

Bone marrow transplantation·2016
Same author

Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.

Journal of viral hepatitis·2016
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Higher platelet doses significantly improve platelet increment and extend transfusion intervals in thrombocytopenic patients. This approach reduces the number of platelet transfusions and donor exposure for patients with hematologic malignancies.

Area of Science:

  • Hematology
  • Transfusion Medicine
  • Oncology

Background:

  • Early recommendations for prophylactic platelet transfusion used a standard dose (0.5 x 10^11/10 kg).
  • This dose lacked robust supporting data.
  • Platelet transfusion efficacy in thrombocytopenic patients with hematologic malignancies requires dose-response evaluation.

Purpose of the Study:

  • To prospectively investigate the dose-response relationship of platelet transfusions in adults and children with hematologic malignancies.
  • To determine optimal platelet dosing for improved clinical outcomes.

Main Methods:

  • Prospective study involving medium, high, and very high doses of fresh ABO-compatible apheresis platelet concentrates (APC).
  • Doses defined by platelet count ranges for adults and children.

Related Experiment Videos

  • End points included platelet increment, recovery, and transfusion interval, analyzed using paired t-tests.

    • Main Results:

    • Higher platelet doses (high and very high) significantly increased platelet increment and transfusion intervals in adults compared to medium doses.
    • Platelet recovery was similar across all doses in adults.
    • Similar positive dose-effect observed in children, with higher doses yielding 1.5-2 fold increases in post-transfusion counts and intervals.
    • Benefits were noted regardless of pre-transfusion clinical status, with greater impact in patients without factors impairing platelet recovery.

    Conclusions:

    • Transfusion of higher platelet doses is more effective in improving platelet counts and extending transfusion intervals.
    • Higher doses can reduce the frequency of platelet transfusions required.
    • Increased dosing strategies significantly decrease donor exposure for thrombocytopenic patients.